Clinical Trial

Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study evaluates the effects of Ginkgo biloba on blood biomarkers related to Alzheimer's disease in patients with mild cognitive impairment. Participants will be randomly assigned to receive either Ginkgo biloba or a placebo for 6 months. Changes in blood biomarkers, including p-tau217 and neurofilament light (NfL), as well as cognitive function, will be assessed to determine whether Ginkgo biloba may influence disease-related biological processes.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-05.
Trial Details
NCT Number NCT07579689
Lead Sponsor Hanyang University
Collaborators: SK Chemicals
Conditions Mild Cognitive Impairment, Alzheimer's Disease
Enrollment 120 participants
Start Date 2026-06
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-26